DS
CCCC icon

David Shaw’s C4 Therapeutics CCCC Stock Holding History

David Shaw’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13M Buy
1,740,989
+680,658
+64% +$2.33M ﹤0.01% 2006
2026
Q1 		$2.79M Buy
1,060,331
+1,007,452
+1,905% +$2.37M ﹤0.01% 2655
2025
Q4 		$101K Buy
52,879
+41,016
+346% +$97.2K ﹤0.01% 4396
2025
Q3 		$26.3K Sell
11,863
-77,612
-87% -$186K ﹤0.01% 4428
2025
Q2 		$128K Buy
89,475
+10,200
+13% +$14.8K ﹤0.01% 4106
2025
Q1 		$127K Buy
79,275
+2,796
+4% +$8.34K ﹤0.01% 3996
2024
Q4 		$275K Sell
76,479
-42,413
-36% -$211K ﹤0.01% 3937
2024
Q3 		$678K Sell
118,892
-237,320
-67% -$1.43M ﹤0.01% 3520
2024
Q2 		$1.65M Sell
356,212
-140,331
-28% -$837K ﹤0.01% 2832
2024
Q1 		$4.06M Buy
496,543
+252,905
+104% +$1.96M ﹤0.01% 2048
2023
Q4 		$1.38M Sell
243,638
-190,472
-44% -$434K ﹤0.01% 2921
2023
Q3 		$807K Sell
434,110
-85,069
-16% -$259K ﹤0.01% 3182
2023
Q2 		$1.43M Buy
519,179
+325,018
+167% +$1.04M ﹤0.01% 2869
2023
Q1 		$610K Buy
194,161
+108,200
+126% +$637K ﹤0.01% 3453
2022
Q4 		$507K Sell
85,961
-44,121
-34% -$366K ﹤0.01% 3840
2022
Q3 		$1.14M Buy
130,082
+51,294
+65% +$533K ﹤0.01% 3496
2022
Q2 		$594K Buy
+78,788
New +$693K ﹤0.01% 3999
2022
Q1 		– Sell
-25,735
Closed -$829K – 5565
2021
Q4 		$829K Buy
25,735
+15,852
+160% +$627K ﹤0.01% 4085
2021
Q3 		$442K Sell
9,883
-6,649
-40% -$285K ﹤0.01% 4156
2021
Q2 		$626K Buy
16,532
+11,102
+204% +$398K ﹤0.01% 3913
2021
Q1 		$201K Sell
5,430
-7,144
-57% -$284K ﹤0.01% 3853
2020
Q4 		$417K Buy
+12,574
New +$365K ﹤0.01% 3470

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's CCCC Position: Q2 2026 in Review

David Shaw increased its C4 Therapeutics (CCCC) stake by 64% in Q2 2026, buying an estimated $2.33M and bringing the position to 1,740,989 shares worth $8.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

David Shaw first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • David Shaw held 1,740,989 shares of C4 Therapeutics worth $8.13M as of Q2 2026.
  • David Shaw bought 680,658 C4 Therapeutics shares in Q2 2026, an estimated $2.33M.
  • C4 Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2006 holding.
  • David Shaw first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.